Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2009

01-10-2009 | Original Article

Physicians make different decisions from nephrologists at serum creatinine 2.0 mg/dl

Authors: Kaichiro Tamba, Eiji Kusano, Kaoru Tabei, Eiji Kajii, Yasushi Asano

Published in: Clinical and Experimental Nephrology | Issue 5/2009

Login to get access

Abstract

Background

It is very important, but not clear, how physicians differ from nephrologists in treatment of renal insufficiency.

Aim

To demonstrate differences in decision-making in treatment of renal insufficiency between physicians and nephrologists.

Design of study

Postal questionnaire.

Setting

All physicians were graduates from one medical school and certified by the Japanese Society of Internal Medicine. Nephrologists were certified by the Society and the Japanese Society of Nephrology.

Method

Questionnaires were sent to 1,395 physicians and 385 nephrologists, including audit of serum creatinine concentration that would indicate referral to nephrologist, audit of continuation of angiotensin converting enzyme inhibitor (ACEI) for a case of renal insufficiency and mild hyperkalemia due to ACEI. Outputs were proportion that selected “serum creatinine 177 μmol/l (2.0 mg/dl) and over” as a referral point to the nephrologist, and proportion that chose “suspend ACEI” for a case of renal insufficiency and mild hyperkalemia due to ACEI.

Results

Six hundred and fourteen physicians replied (44%), and 111 certified in internal medicine were extracted from them. One hundred and eighty-six certified nephrologists replied (47%), and 114 certified in internal medicine were extracted. The proportion that chose “177 μmol/l” as a referral point to the nephrologist was 20% for physicians and 61% for nephrologists (P < 0.0001). An additional 17% of nephrologists recommended creatinine concentration below 177 μmol/l, whereas no such opinion was found among physicians. The proportion that chose “suspend ACEI” was 45% for physicians and 16% for nephrologists (P < 0.0001).

Conclusion

There is significant difference between decisions made by physicians and nephrologists regarding treatment for patients with serum creatinine concentration of 177 μmol/l.
Literature
1.
go back to reference Nakai S, Masakane I, Shigematsu T, Hamano T, Yamagata K, Watanabe Y, et al. An overview of dialysis treatment in Japan (as of Dec. 31, 2007). J Jap Soc Dial Ther. 2009;42:1–45.CrossRef Nakai S, Masakane I, Shigematsu T, Hamano T, Yamagata K, Watanabe Y, et al. An overview of dialysis treatment in Japan (as of Dec. 31, 2007). J Jap Soc Dial Ther. 2009;42:1–45.CrossRef
2.
go back to reference Winkelmayer WC, Owen WF, Levin R, Avorn J. A propensity analysis of late versus early nephrologist referral and mortality on dialysis. J Am Soc Nephrol. 2003;14:486–92.CrossRefPubMed Winkelmayer WC, Owen WF, Levin R, Avorn J. A propensity analysis of late versus early nephrologist referral and mortality on dialysis. J Am Soc Nephrol. 2003;14:486–92.CrossRefPubMed
3.
go back to reference Obrador GT, Pereira BJ. Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure. Am J Kidney Dis. 1998;31:398–417.CrossRefPubMed Obrador GT, Pereira BJ. Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure. Am J Kidney Dis. 1998;31:398–417.CrossRefPubMed
4.
go back to reference Schmidt RJ, Domico JR, Sorkin MI, Hobbs G. Early referral and its impact on emergent first dialyses, health care costs, and outcome. Am J Kidney Dis. 1998;32:278–83.CrossRefPubMed Schmidt RJ, Domico JR, Sorkin MI, Hobbs G. Early referral and its impact on emergent first dialyses, health care costs, and outcome. Am J Kidney Dis. 1998;32:278–83.CrossRefPubMed
5.
go back to reference National Kidney Foundation. K/DOQI, clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1–266. National Kidney Foundation. K/DOQI, clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1–266.
6.
go back to reference Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.CrossRefPubMed Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.CrossRefPubMed
7.
go back to reference Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;10:1963–74.CrossRefPubMed Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant. 1995;10:1963–74.CrossRefPubMed
8.
go back to reference Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939–45.CrossRefPubMed Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939–45.CrossRefPubMed
9.
go back to reference Japanese Society for Nephrology (2007). Clinical practice guidebook for diagnosis and treatment of chronic kidney disease. Tokyo-igakusha. Japanese Society for Nephrology (2007). Clinical practice guidebook for diagnosis and treatment of chronic kidney disease. Tokyo-igakusha.
10.
go back to reference Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.CrossRefPubMed Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.CrossRefPubMed
11.
go back to reference Kalra PA, Kumwenda M, MacDowall P, Roland MO. Questionnaire study and audit of use of angiotensin converting enzyme inhibitor and monitoring in general practice: the need for guidelines to prevent renal failure. BMJ. 1999;318:234–7.CrossRefPubMedPubMedCentral Kalra PA, Kumwenda M, MacDowall P, Roland MO. Questionnaire study and audit of use of angiotensin converting enzyme inhibitor and monitoring in general practice: the need for guidelines to prevent renal failure. BMJ. 1999;318:234–7.CrossRefPubMedPubMedCentral
12.
go back to reference de Lusignan S, Chan T, Stevens P, O’Donoghue D, Hague N, Dzregah B, et al. Identifying patients with chronic kidney disease from general practice computer records. Fam Pract. 2005;22:234–41.CrossRefPubMed de Lusignan S, Chan T, Stevens P, O’Donoghue D, Hague N, Dzregah B, et al. Identifying patients with chronic kidney disease from general practice computer records. Fam Pract. 2005;22:234–41.CrossRefPubMed
13.
go back to reference Akbari A, Swedko PJ, Clark HD, Hogg W, Lemelin J, Magner P, et al. Detection of chronic kidney disease with laboratory reporting of estimated glomerular filtration rate and an educational program. Arch Intern Med. 2004;164:1788–92.CrossRefPubMed Akbari A, Swedko PJ, Clark HD, Hogg W, Lemelin J, Magner P, et al. Detection of chronic kidney disease with laboratory reporting of estimated glomerular filtration rate and an educational program. Arch Intern Med. 2004;164:1788–92.CrossRefPubMed
14.
go back to reference Tian S, Kusano E, Ohara T, Tabei K, Itoh Y, Kawai T, et al. Cystatin C measurement and its practical use in the patients with various renal diseases. Clin Nephrol. 1997;48:104–8.PubMed Tian S, Kusano E, Ohara T, Tabei K, Itoh Y, Kawai T, et al. Cystatin C measurement and its practical use in the patients with various renal diseases. Clin Nephrol. 1997;48:104–8.PubMed
15.
go back to reference Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001;37:79–83.CrossRefPubMed Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001;37:79–83.CrossRefPubMed
16.
go back to reference Ichihara K, Saito K, Itoh Y. Sources of variation and reference intervals for serum cystatin C in a healthy Japanese adult population. Clin Chem Lab Med. 2007;45:1232–6.CrossRefPubMed Ichihara K, Saito K, Itoh Y. Sources of variation and reference intervals for serum cystatin C in a healthy Japanese adult population. Clin Chem Lab Med. 2007;45:1232–6.CrossRefPubMed
Metadata
Title
Physicians make different decisions from nephrologists at serum creatinine 2.0 mg/dl
Authors
Kaichiro Tamba
Eiji Kusano
Kaoru Tabei
Eiji Kajii
Yasushi Asano
Publication date
01-10-2009
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2009
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-009-0176-4

Other articles of this Issue 5/2009

Clinical and Experimental Nephrology 5/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine